Form 4 JOHNSON & JOHNSON For: Sep 02 Filed by: Schmid Timothy

Fri, 04 Sep 2026 09:08:00 -0400

si-local-file:///var/storage/secattach/20260904/27028024.html

Johnson & Johnson to Participate in the Deutsche Bank 2026 Healthcare Summit

Wed, 02 Sep 2026 16:21:00 -0400

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)-- Johnson & Johnson (NYSE: JNJ) will present at the Deutsche Bank 2026 Healthcare Summit on Thursday, September 17th, 2026. Management will participate in a Fireside Chat at 12:00 p.m. Eastern Time.

A live audio webcast of the presentation will be accessible through Johnson & Johnson’s Investor Relations website at www.investor.jnj.com. An archived edition of the session will be available later that day.

The audio webcast replay will be available approximately 48 hours after the webcast.

View source version on businesswire.com:

Johnson & Johnson to Participate in the Deutsche Bank 2026 Healthcare Summit

Wed, 02 Sep 2026 16:21:00 -0400

The audio webcast replay will be available approximately 48 hours after the webcast.

View source version on businesswire.com:

Form 144 JOHNSON & JOHNSON Filed by: Schmid Timothy

Wed, 02 Sep 2026 11:27:00 -0400

si-local-file:///var/storage/secattach/20260902/27017381.html

Form 3 JOHNSON & JOHNSON For: Sep 01 Filed by: Cavanaugh Thomas

Tue, 01 Sep 2026 16:52:00 -0400

si-local-file:///var/storage/secattach/20260901/27013591.html

Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results

Mon, 31 Aug 2026 17:08:00 -0400

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)-- Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, October 13th to review third-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Ryan Koors, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson & Johnson’s executive team.

Investors and other interested parties can access the webcast/conference call in the following ways:

The webcast and presentation material are accessible at

Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results

Mon, 31 Aug 2026 17:08:00 -0400

Investors and other interested parties can access the webcast/conference call in the following ways:

The webcast and presentation material are accessible at

FDA: issues early alert on Abiomed heart pump controller purge cassette issue

Wed, 26 Aug 2026 14:00:37 -0400

(Updated - August 26, 2026 2:00 PM EDT)

FDA: issues early alert on Abiomed heart pump controller purge cassette issue

FDA: as of August 17, Abiomed has reported 37 serious injuries & 3 deaths associated with heart pump controller purge cassette issue.

FDA: issues early alert on Abiomed heart pump controller purge cassette issue

Wed, 26 Aug 2026 14:00:37 -0400

(Updated - August 26, 2026 2:00 PM EDT)

FDA: issues early alert on Abiomed heart pump controller purge cassette issue

FDA: as of August 17, Abiomed has reported 37 serious injuries & 3 deaths associated with heart pump controller purge cassette issue.

FDA approves Johnson & Johnson drug for rare blood disorder

Mon, 24 Aug 2026 19:13:04 -0400

The U.S. Food and Drug Administration has approved Johnson & Johnson's (NYSE: JNJ) IMAAVY (nipocalimab-aahu) for the treatment of warm autoimmune hemolytic anemia (wAIHA), a rare condition in which autoantibodies destroy red blood cells, causing severe anemia. The approval marks the first time a therapy has been cleared specifically for wAIHA.